Scientific Program

CARs for Kids - Chimeric Antigen Receptor T-cell Therapy for Childhood Leukemias

<span>Scientific Committee on Blood Disorders in Childhood</span>

The field of cellular therapies has exploded in recent years. There are exciting advances being made in CAR T therapy for children, in not only B-ALL but also T-ALL and AML. In addition, studies are now focused beyond initial therapy to next line concepts such as preventing relapse. This session will bring together scientists in the area of cellular therapies that will be of interest to both pediatric providers and all other scientists and clinicians working in the area of cellular therapies and leukemia. Furthermore, the techniques discussed will be valuable for patients of all ages, linking hematology across the age continuum. Attendees for this session will have a better understanding of how CAR T-cells are being created and manipulated to treat relapse or refractory ALL, AML and T-cell ALL and what new therapies are on the horizon.

Chair:

Julie Jaffray
Rady Children's Hospital, University of California, San Diego
San Diego, CA, United States

Speakers:

Sara Ghorashian
Great Ormond Street Institute of Child Health
London, ENG, United Kingdom
CAR T-Cell Breakthroughs: Shaping the Future of B-Cell ALL Treatment

Maksim Mamonkin
Baylor College of Medicine
Houston, TX, United States
T-Cell ALL Meets CAR-T: Advancements and Breakthroughs

Mireya Paulina Velasquez
St. Jude Children's Hospital
Memphis, TN, United States
Harnessing CAR-T: A New Era in AML Treatment

back to top

JOINT SESSION: The Emerging Landscape of Germline Predisposition to Bone Marrow Failure and Leukemia

<span>Scientific Committee on Bone Marrow Failure and Scientific Committee on Myeloid Neoplasia</span>

There is a rapid expansion in the discovery and characterization of factors underlying genetic predisposition to bone marrow failure and hematologic malignancy risk. The first talk will focus on recent studies using a genome-first approach to define the population prevalence of germline variants in genes causing inherited bone marrow failure syndromes (IBMFS) and leukemia predisposition syndromes and discuss the implications of this expanded recognition of prevalence on our understanding of clinical phenotypes at the population level. The next talk will discuss the mechanisms that underlie somatic clonal progression in IBMFS and how they inform our understanding of disease-specific malignancy risk. The lessons from IBMFS can also be translated to a more generalized understanding of the gene-specific and context-selective malignancy risk of sporadic clonal hematopoiesis, and the implications of recently defined paradigms in IBMFS on our understanding of clonal hematopoiesis in the general population will be discussed. The final talk will discuss the expanding understanding of DDX41 in leukemia pathogenesis, highlighting recently described molecular mechanisms. The focus will be on how aging-related bone marrow stress in patients with germline DDX41 loss-of-function mutations selects hematopoietic stem cells with "second-hit" DDX41 mutations, contributing to a bone marrow failure-like disorder and malignant progression despite low mutation abundance.

 

 

Chairs:

Sharon Savage
National Cancer Institute
Bethesda, MD, United States

Giuseppe Saglio
Department of Clinical and Biological Sciences
Turin, Torino, Italy

Speakers:

Lisa McReynolds
National Cancer Institute
Bethesda, MD, United States
Inherited susceptibility to bone marrow failure and leukemia is more common than you think

R. Coleman Lindsley
Dana-Farber Cancer Institute
Boston, MA, United States
Beyond Malignancy: How insights from IBMFS inform clonal hematopoiesis malignancy risk more broadly

Timothy Chlon
Cincinnati Children's Hospital
Cincinnati, OH, United States
Defining the biology of DDX41

Pinkal Desai
Weill Cornell Medical College
New York, NY, United States
Somatic mutations may precede acute myeloid leukemia even years before diagnosis

back to top

Harnessing The Hemostasis Interactome for Novel Insights and Mechanisms of Coagulation Proteins

<span>Scientific Committee on Hemostasis</span>

Coagulation protein structure-function is foundational for developing therapies for bleeding and clotting disorders. Most disorders are associated with high morbidity and mortality and in 2025, there is an urgent need for targeted therapeutics to improve the lives of affected patients. The excellent speakers chosen for this session will influence the audience to explore novel approaches in understanding protein structure and functions of key molecules involved in hemostasis. Talk 1 is focused on advances in structural methods and how they have contributed to recent discoveries of functional relationships of the hemostasis interactome. Talk 2 is focused on a biological approach and recent advances in understanding activities of the prothrombinase interactome and modulation of Factor V activity by the protein C pathway. Talk 3 will describe genetic approaches to obtain structure-function understanding of coagulation proteins with therapeutic relevance to hemophilia. 

At the end of the session the audience will gain new insights on coagulation protein structure-function and how it is preparing the way for the next generation of therapeutic variants for thrombotic and hemorrhagic conditions. 

Chair:

Rinku Majumder
LSU Health Science Center
New Orleans, LA, United States

Speakers:

Enrico Di Cera
Saint Louis University School of Medicine
St Louis, MO, United States
Unveiling the Hemostasis Interactome: A Structure-Guided Discovery of Blood's Hidden Secrets

Rodney Camire
University of Pennsylvania
Philadelphia, PA, United States
Unlocking the Hemostasis Interactome: Activity-Guided Discovery of Blood's Key Connections

Raja Prince
University of Bern
Bern, Switzerland
Decoding the Hemostasis Interactome: A Genetics-Guided Exploration of Blood’s Blueprint

back to top

New Frontiers in Neutrophil Biology

<span>Scientific Committee on Immunology and Host Defense</span>

Neutrophils are the most abundant white blood cell of the blood and are a critical first line of defense against bacterial infections. Their importance is highlighted by the tremendous clinical impact of fever and neutropenia, congenital neutropenias, chronic granulomatous disease, and other neutrophil disorders. Recent studies have shifted traditional views of neutrophil ontogeny, function, and role in disease.

Dr. Renato Ostuni will discuss his work using single cell approaches to uncover aspects of neutrophil ontogeny and heterogeneity.

Dr. Dominique Bonnet will discuss effects of clonal hematopoiesis associated mutations such as TET2 on neutrophil function.

Dr. Emily Findlay will elucidate recently discovered roles of neutrophils in T cell activation and cross talk with the adaptive immune system.

Far from the simple automatons we once thought they were, neutrophils are revealed to be a highly diverse collection of cells which serve a critical role in immunity but may also contribute to disease states including cardiovascular disease, autoimmunity, and immune escape by tumors.

Chair:

Katherine King
Baylor College of Medicine
Houston, TX, United States

Speakers:

Renato Ostuni
San Raffaele Scientific Institute
Milan, N/A, Italy
Single Cell Insights Into Neutrophil Ontogeny

Dominique Bonnet
The Francis Crick Institute
London, ENG, United Kingdom
Effect on Clonal Hematopoiesis Associated Mutations on Neutrophil Function

Emily Findlay
University of Edinburgh
Edinburgh, SCO, United Kingdom
Neutrophils in Tumor Immunity

back to top

Iron and Heme Metabolism and Its Considerations in Understanding Pathophysiology and Therapy

<span>Scientific Committee on Iron and Heme</span>

Iron dysregulation is frequently a consequence of hematopoietic disorders caused by genetic defects not directly related to iron. In hematopoietic conditions such as sickle cell diseases, patients are anemic but paradoxically have iron overload in storage tissues. Treating the iron overload or deficiency can significantly decrease morbidity and mortality and significantly increase quality of life. This session highlights basic science and clinical advances related to understanding and targeting iron dysregulation in managing hematopoietic conditions.  Talk 1 highlights how mishandling of heme, the most abundant chemical form of iron in blood, can cause toxicity in organ systems and exacerbate the severity of sickle cell disease.  Talk 2 takes on a clinical focus, discussing how iron dysregulation exacerbates the physiologic stress of pregnancy, and advances in diagnosing  and treating iron deficiency in this population. Talk 3 ends the session by highlighting how recent basic science advances in iron biology have catalyzed the development of genetic therapies for iron mislocalization or dysregulation in hematopoietic diseases. The session is timely because they tie together basic science studies from the “golden age of iron” and show how these studies gave insight into the intersection between iron dysregulation and disease pathogenesis.  The take home message for the audience is that iron dysregulation can be a consequence of hematopoietic or physiological stress conditions, and targeting iron dysregulation can be an important adjunct to alleviating the severity of these conditions and may inform the standard of care in treatment.

Chair:

Yvette Yien
University of Pittsburgh
Pittsburgh, PA, United States

Speakers:

Samit Ghosh
Univ. of Pittsburgh-Of The Commonwealth System of Higher Edu
Pittsburgh, PA, United States
Heme Trafficking and Its Role in Modifying Physiology and Hematopoietic Diseases

Michelle Sholzberg
University of Toronto
Toronto, Ontario, Canada
Iron Deficiency/Overload and Its Considerations In Design of Therapeutic Strategies.

Stefano Rivella
Children’s Hospital of Philadelphia
Philadelphia, PA, United States
Targeting Iron Deficiency/Overload as a Therapeutic Strategy in Treating Hematologic Disease

back to top

Innovative Models of Lymphoma

<span>Scientific Committee on Lymphoid Neoplasia</span>

The biology of lymphomas is complex, characterized by both genetic and non-genetic alterations in lymphoma cells, as well as perturbed crosstalk with the tumor microenvironment, all of which influence clinical course and treatment outcomes. Model systems are essential for elucidating these complex biological processes and the mechanisms driving lymphoma development, progression, and treatment resistance within a controlled and reproducible environment. Recent advancements in the field have significantly improved our ability to accurately model human lymphoma. The session will provide a comprehensive overview of novel and innovative models increasingly available for studying lymphoma, with a particular emphasis on the tumor microenvironment. The presentations will cover ex vivo and in vivo models, including refined lymphoma transplantation strategies and genetically engineered mouse models, focusing on their individual strengths and limitations. By attending this session, attendees will enhance their understanding of how these models can be optimally utilized to advance their knowledge of lymphoma biology and treatment effects, facilitating the translation of research findings into clinical applications.

Chair:

Oliver Weigert
Ludwig-Maximilians-University (LMU) Hospital
Munich, Germany

Speakers:

Ankur Singh
Georgia Institute of Technology
Atlanta, GA, United States
Bioengineering Synthetic Lymphoma Models: Advancements in Ex Vivo Systems

Michael R Green
MD Anderson Medical Center
Houston, TX, United States
Utilizing Refined Lymphoma Models for Treatment Studies: Innovations in Syngeneic Transplants, Patient-Derived Xenografts, and Humanized Mouse Model

Wendy Béguelin
Weill Cornell Medical College
New York, NY, United States
Genetically Engineered Mouse Models (GEMMs): Dissecting Subtype Specific Biologies

back to top

The Critical Role of Metabolism in Megakaryocyte and Platelet Biology

<span>Scientific Committee on Megakaryocytes and Platelets</span>

Metabolism is critical in regulating cellular function across a wide range of biological processes. However, much remains unknown about how metabolic pathways influence their development and function in the context of megakaryocytes and platelets. Emerging evidence suggests that platelet function can be significantly affected by metabolic changes, which can also impair the process of thrombopoiesis. Recent publications have highlighted the importance of studying the metabolic regulation in these cells, opening new avenues for understanding how metabolism may impact platelet production and function, as well as its implications in disease states. This is a novel topic in the megakaryocyte and platelet field. The session will span basic and translational research addressing how mitochondria morphology, lipid metabolism, and altered metabolism impact platelet activation, production, and possibly platelet disorders. 

Chair:

Alessandra Balduini
Tufts University
Medford, MA, United States

Speakers:

Jesse Rowley
UNIVERSITY OF UTAH HEALTH
Salt Lake City, UT, United States
Mitochondria Morphology, Function and Platelet Activation Responses

Koji Eto
Center for iPS Cell Research and Application, Kyoto University
Kyoto, KYO, Japan
Lipid Metabolism, Megakaryocyte Function and Platelet Production

Kathleen Freson
Katholieke Universiteit Leuven, Department of Cardiovascular Sciences
Leuven, -, Belgium
Altered Metabolisms and Platelet Disorders

back to top

Mechanisms that Direct and Derail Lineage-Specific Transcription Factor Complexes

<span>Scientific Committee on Myeloid Biology</span>

During normal myelopoiesis, cell fate decisions are directed by the totality of mechanisms that create the effective transcriptome defining the cell’s identity. When misappropriated, these mechanisms derail differentiation and drive malignancies. This session will explore new frontiers in multilayer transcriptome regulation mechanisms that shape lineage-specific programs and that go awry during abnormal myelopoiesis and malignancy. We will first focus on liquid-liquid phase separation mechanisms in the biogenesis of P-bodies and selective sequestration of mRNAs for fine-tuning lineage fate specification. We will then highlight recent discoveries into transcription dynamics observed through single-molecule visualization of transcriptional bursts, implicating transcriptional noise as driving subclonal heterogeneity, stem cell plasticity, and fate decisions. Finally, we will explore recent advances in the understanding of chromatin regulatory complexes in the maintenance, proliferation and differentiation of normal and leukemic hematopoietic stem cells.

Chair:

Olga A Guryanova
University of Florida
Gainesville, FL, United States

Speakers:

Bruno Di Stefano
Baylor College of Medicine
Houston, TX, United States
Phase Separation in Myeloid Malignancies

Ulrich Steidl Jr, PhD, MD
Albert Einstein College of Medicine - Montefiore Einstein
Bronx, New York, United States
Abnormal Transcription Factor Complexes in Myeloid Leukemia

Julie Lessard
Institute For Research In Immunology and Cancer
Montreal, QC, Canada
Chromatin Remodeling in Normal and Malignant Myelopoiesis

back to top

Exploring the Origins of Multiple Myeloma: Germline Predisposition and Early Deregulations

<span>Scientific Committee on Plasma Cell Neoplasia</span>

The question of germline predisposition and the cell of origin is crucial in multiple myeloma (MM)  for understanding the phylogeny of the disease and advancing therapeutic strategies aimed at finding a cure. Recent advances in large-scale genomics and single-cell technologies have significantly enhanced our capacity to investigate germline predisposition and early molecular deregulation in MM. Over the past year, several key studies have been published or presented, bringing new understanding in germline variants (over 30 are now identified and several are functionally validated). Additionally recent large-scale single-cell analyses of several millions of cells have provided new insights into of the disease’s origin and progression both at the tumor and microenvironmental levels. This session is particularly timely, because it will reflect the latest critical publications in this area. The audience will gain new insights into the origins of MM, exploring the complex interplay of early genetic events and environmental factors that contribute to its development, as well as the implications of these findings for future therapeutic strategies.

Chair:

Salomon Manier
Lille University Hospital
Lille, N/A, France

Speakers:

Celine Vachon
Mayo Clinic
Rochester, MN, United States
Germline Genetic Variants and Predisposition to Multiple Myeloma

Rodger Tiedemann
University of Aukland
Auckland, New Zealand
Identifying and Characterizing the Cells of Origin in Multiple Myeloma

Romanos Sklavenitis-Pistofidis
Dana-Farber Cancer Institute
Boston, MA, United States
Early Molecular and Immune Deregulations in Premalignant Conditions

back to top

Thromboinflammation

<span>Scientific Committee on Thrombosis &amp; Vascular Biology</span>

This session of the Scientific on Thrombosis and Vascular Biology focuses on the links between inflammation and thrombosis.  The cellular and molecular players, and this potential therapies, involved are where hematologists are comfortable. The linkage of these processes plays roles in many diseases where hematologists are consulted on. We have chosen three focused topics that cover this broad but hot area. Dr. Luisa Iruela-Arispe's talk will be "Burning (Inflamed) Endothelium: Endothelial Chemo-Mechanical Signaling In Response to Shear Stress".  Dr. Markus Sperandio will introduce the Inflammasome and discuss E-selectin-Driven activation. Finally Dr. Sonata Jodele will discuss how how complement interacts, in a talk titled Complement on Fire. 

 

 

Chair:

Peter Gross
Toronto General Hospital
Toronto, ON, Canada

Speakers:

Sonata Jodele
Cinncinati Children's
Cincinnati, OH, United States
Complement On Fire

Markus Sperandio
Ludwig-maximilians-University
Planegg-Martinsried, Germany
The Inflammasone: E-selection-Driven Activation

Luisa Iruela-Arispe
University of California, Los Angeles
Los Angeles, CA, United States
Burning (Inflamed) Endothelium

back to top

TRIMming the Immune Response: Cutting Edge Insights into Transfusion-Related Immunomodulation

<span>Scientific Committee on Transfusion Medicine</span>

Transfusions remain a life-saving treatment, and yet can elicit a complex host immune response, characterized by a combination of proinflammatory and/or immunosuppressive outcomes. These responses, also termed transfusion-related immunomodulation (TRIM), are shaped by molecular characteristics of the transfused product and intrinsic cellular signaling pathways within the recipient’s immune cells, which govern how they perceive and react to transfused components.  The session on TRIM aims to discuss recent insights into immunomodulatory properties of transfusion components that can lead to potentiation and/or suppression of immune response in the transfusion recipient. By attending the session, the audience will learn about recent progress in understanding the molecular and cellular processes that underlie the immunomodulatory effects of transfused products, including the role of immune mediators released into the collection bag or present on donor components, as well as the immune response of the transfusion recipient. 

Chair:

France Pirenne
University Paris-Est Créteil
Creteil, France

Speakers:

Benoit Vingert
INSERM U955
Creteil, France
Little Secrets: Microparticles in Blood Products as Immune Modulators

Nilam Mangalmurti
Perelman School of Medicine
Philadelphia, PA, United States
Donor Alert: Immunomodulatory Roles of Red Blood Cells

Karina Yazdanbakhsh
New York Blood Center
New York, NY, United States
Special Effects: Recipient Innate Immunity and Transfusion Immunomodulation

back to top

JOINT SESSION. Game of Clones: The Evolution of Hematopoiesis from Birth to Aging

<span>Scientific Committee on&nbsp;Hematopathology and Clinical Laboratory Hematology&nbsp;</span>

This session explores recent advances in understanding hematopoiesis across the human lifespan, beginning with early mutations in hematopoietic stem cells (HSCs) during embryogenesis. These early mutations and their associated genetic and epigenetic regulators provide a competitive advantage to certain HSC clones, reshaping clonal dynamics over time. As individuals age, chronic inflammation further exacerbates stem cell dysregulation, leading to the expansion of these mutant clones. The consequences of clonal hematopoiesis, particularly its role in increasing the risk of hematologic malignancies, will also be examined. Emerging research utilizing single-cell and barcoding technologies allows for more precise tracking of clonal changes, providing new insights into disease progression and risk prediction. Attendees will gain a deeper understanding of how these early-life mutations and age-related clonal expansions are reshaping the approach to diagnosing and managing hematologic disorders, aligning with the broader goals of advancing hematology research and improving patient outcomes.

Chairs:

Peter van Galen
Brigham and Women´s Hospital
Boston, MA, United States

Ingo Ringshausen
University College London
London, London, United Kingdom

Speakers:

Adam Mead
University of Oxford
Oxford, ENG, United Kingdom
Embryogenesis and Early Mutations in Hematopoietic Stem Cells

Grant Challen
Washington University
St Louis, MO, United States
Genetic-Epigenetic Regulators Providing a Competitive Advantage to HSCs

Michael Milsom
DKFZ, Heidelberg, Germary
Heidelberg, Germany
Inflammation and Expansion of Dysregulated Stem Cells

Nancy Gillis
Moffitt Cancer Center
Tampa, FL, United States
Clonal Hematopoiesis: The Good, the Bad, and the Unknown

back to top

Dissecting Enhancer Function in Hematopoietic Development and Disease

Scientific Committee on Epigenetics and Genomics

New developments in imaging, spatial transcriptomics, genetic manipulation, single-cell methods, and systems approaches in computational biology are enabling the dissection of cis-regulatory elements at unprecedented resolution. These techniques are uncovering new aspects of enhancer biology and function, such as what regulatory elements comprise a "super-enhancer". This session will highlight recent findings stemming from these innovative techniques in the activity of enhancers in regulating gene expression in normal and malignant hematopoiesis. The audience will learn about how these cutting-edge approaches are informing our understanding of hematopoietic transcriptional regulation in normal and disease states.

Chair:

Megan McNerney
The University of Chicago
Chicago, IL, United States

Speakers:

Anders Hansen
MIT Biological Engineering
Cambridge, MA, United States
Imaging and Systems Biology Approaches For Studying Enhancer Activity

Martin Rivas
University of Miami
Miami, FL, United States
Enhancer Function in Lymphoid Development and Lymphoma

Mira Kassouf
Oxford University
OXFORD, ENG, United Kingdom
Multi-partite Enhancer Assembly and Chromatin Architecture

back to top

Flipping the Switch: Fetal Hemoglobin Reactivation for Treating Hemoglobin Disorders – From Mechanism to Therapy

Scientific Committee on Red Cell Biology

Fetal hemoglobin (HbF) reactivation is a validated therapeutic strategy for hemoglobin disorders such as sickle cell disease and β-thalassemia. These disorders are characterized by mutations in adult hemoglobin (HbA) genes, leading to abnormal hemoglobin function. Reactivating HbF can ameliorate disease symptoms by reducing polymerization of sickle hemoglobin (HbS) in sickle cell disease and by increasing total hemoglobin production in β-thalassemia. This can be achieved through targeting key transcriptional regulators such as BCL11A, which normally suppresses HbF expression postnatally. Advances in gene-editing technologies, particularly CRISPR-Cas9, now enable precise modulation of HbF reactivation by disrupting regulatory elements of BCL11A or directly editing HbF promoters.

Therapeutic editing approaches aimed at increasing HbF levels hold significant potential to offer durable, one-time treatments for hemoglobinopathies. This rapidly advancing field has profound implications for understanding and treating common red blood cell disorders. This session will highlight recent discoveries in hemoglobin gene regulation, novel strategies to reactivate HbF, and the latest basic and translational advances in gene therapy for hemoglobin disorders.

The audience will learn the latest advances in identifying novel regulators of hemoglobin gene regulation, developing new approaches to reactivate HbF, and the basic and translational studies of gene therapy approaches for treating hemoglobin disorders.

Chair:

Jian Xu
St. Jude Children's Research Hospital
Memphis, TN, United States

Speakers:

Merlin Crossley
School of Biotechnology and Biomolecular Sciences
University of NSW, NSW, NSW, Australia
Identifying and Targeting New Regulators of Hemoglobin Switching

Daniel Bauer
Harvard Medical School
Boston, MA, United States
Preclinical Development of Gene Editing Approaches for Hemoglobin Disorders

Giuliana Ferrari
Istituto Scientifico H. San Raffaele
Milan, Italy, Italy
Developing Gene Therapy Approaches for Treating Hemoglobin Disorders

back to top

Tracing Bloodlines: Decoding Embryonic Waves of Blood Cell Production and Their Contribution to Disease.

Scientific Committee on Stem Cells and Regenerative Medicine

Advances in genetic lineage tracing, barcoding, imaging and single cell sequencing and functional assays has fundamentally changed our understanding of the ontogeny of the hematopoietic system in recent years. We now understand that rather than the classic view of three main waves of primitive and definitive blood production, there are many more overlapping waves of hematopoietic specification during ontogeny that generate a diverse array of short and long-lived hematopoietic populations, many of which persist long into adulthood and shape the adult blood system and bone marrow niche. Further, evidence is emerging that the hematopoietic hierarchy of stem and progenitor cells emerges not in a linear path from hematopoietic stem cell to progenitor, but rather a multitude of stem and progenitor cells likely emerge independently in overlapping waves from a functionally diverse hemogenic endothelium and persist long into adulthood. Indeed, the gradual exhaustion of some of these populations with age may contribute to aging-related phenotypes of the hematopoietic system. It is also becoming clear that the transition from fetal to adult identities occurs not only at the level of stem and progenitor cells, but also in downstream mature blood cells, some of which play key roles in shaping the developing blood system and its supportive niche and also hematologic disease. This session and the speakers will review recent findings in this area. 

Chair:

Shannon McKinney-Freeman
St. Jude Children's Research Hospital
Memphis, TN, United States

Speakers:

Momoko Yoshimoto
Western Michigan University Homer Stryker MD School of Medicine
Kalamazoo, MI, United States
New Insights Into the Dynamics and Heterogeneity of Waves of Blood Production During Development

Claudia Waskow
Leibniz Institute on Aging, Germany
Jena, Germany
Highlighting the Role of Fetal Blood Cells In Shaping the Life-Long Blood System

Elvin Wagenblast
Icahn School of Medicine/Mount Sinai
New York, NY, United States
Recent Insights Into the Pathophysiology of Hematologic Disease With Fetal Origins

back to top

Strategies To Improve Outcomes After Hematopoietic Cell Transplantation and Adoptive Cell Therapy

Scientific Committee on Transplant Biology &amp; Cellular Therapies

This session will provide an overview of recent advances in both hematopoietic stem cell transplantation and adoptive cellular therapies. Audience are expected to learn about important scientific advances in graft manipulation, including in the application of hematopoietic stem transplantation for non-malignant indications, as well as a timely scientific update on novel strategies to prevent graft-versus-host-disease and recent advances in the fast-evolving field of detecting and treating cytokine release syndrome /immune effector cell-associated neurotoxicity syndrome after CAR-T therapies.

Chair:

Craig Byersdorfer
University of Minnesota
Minneapolis, MN, United States

Speakers:

Marie Bleakley
Fred Hutchinson Cancer Rsch. Ctr.
Seattle, WA, United States
Novel Graft Manipulation Strategies - From Bench to Bedside

Leslie Kean
Boston Children's Hospital
Boston, MA, United States
New Preclinical and Translational Approaches to Prevent GVHD

Kai Rejeski
LMU University Hospital
Munich, Bavaria, Germany
Ways to Predict and/or Minimize Hematotoxicity, Infections and Non-Relapse Mortality After Immunotherapy